Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis

Horellou, Philippe; Wang, Min; Keo, Vixra; Chrétien, Pascale; Serguera, Ché; Waters, Patrick; Deiva, Kumaran

doi:10.1016/j.jneuroim.2015.10.002

Cited by 41 publications

(46 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients were tested locally in the respective reference laboratories of the referring countries for serum anti-MOG and anti-aquaporin 4 (AQP4) antibodies, using live-cell-based assays, as part of standard clinical care while clinically symptomatic [3,4,[9][10][11].…”

Section: Data Collectionmentioning

confidence: 99%

Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome

Wong

Hacohen

Armangué

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Data Collectionmentioning

confidence: 99%

Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome

Wong

Hacohen

Armangué

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…31 A recent pediatric study confirmed these results. 32 IL-6 is secreted following activation of astrocytes and microglia, exerting its effect on oligodendroglia and axons and mediating cellular injury in spinal cord culture sections. 28 There is a correlation between elevated IL-6 levels and disability in patients with ATM.…”

Section: Differential Diagnosis and Evaluationmentioning

confidence: 99%

Pediatric transverse myelitis

et al. 2016

Self Cite

View full text Add to dashboard Cite

Pediatric acute transverse myelitis (ATM) is an immune-mediated CNS disorder and contributes to 20% of children experiencing a first acquired demyelinating syndrome (ADS). ATM must be differentiated from other presentations of myelopathy and may be the first presentation of relapsing ADS such as neuromyelitis optica (NMO) or multiple sclerosis (MS). The tenets of the diagnostic criteria for ATM established by the Transverse Myelitis Consortium Working Group can generally be applied in children; however, a clear sensory level may not be evident in some. MRI lesions are often centrally located with high T2 signal intensity involving gray and neighboring white matter. Longitudinally extensive ATM occurs in the majority. Asymptomatic lesions on brain MRI are seen in more than one-third and predict MS or NMO. The role of antibodies such as myelin oligodendrocyte glycoprotein in monophasic and relapsing ATM and their significance in therapeutic approaches remain unclear. ATM is a potentially devastating condition with variable outcome and presents significant cumulative demands on health and social care resources. Children generally have a better outcome than adults, with one-half making a complete recovery by 2 years. There is need for standardization of clinical assessment and investigation protocols to enable international collaborative studies to delineate prognostic factors for disability and relapse. There are no robust controlled trials in children or adults to inform optimal treatment of ATM, with one study currently open to recruitment. This review provides an overview of current knowledge of clinical features, investigative workup, pathogenesis, and management of ATM and suggests future directions. Neurology ® 2016;87 (Suppl 2):S46-S52 GLOSSARY ADS 5 acquired demyelinating syndrome; AFM 5 acute flaccid myelitis; AQP4 5 aquaporin-4; ASIA 5 American Spinal Injury Association; ATM 5 acute transverse myelitis; GBS 5 Guillain-Barré syndrome; IL 5 interleukin; IVIg 5 IV immunoglobulin; LETM 5 longitudinally extensive TM; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; PLEX 5 plasmapheresis; SLE 5 systemic lupus erythematosus; TMCWG 5 Transverse Myelitis Consortium Working Group.Pediatric acute transverse myelitis (ATM) is an immune-mediated CNS disorder classically described as demyelinating. ATM comprises a subgroup of the noncompressive transverse myelopathies.1,2 It is a potentially devastating condition with variable outcome. 3 ATM must be differentiated from other, rarer presentations of noncompressive myelopathy.4,5 ATM may be the first presentation of relapsing acquired demyelinating syndromes (ADS) such as neuromyelitis optica (NMO) or multiple sclerosis (MS). A PubMed search using the terms "pediatric or paediatric transverse myelitis" revealed that more than 200 articles have been published in English on the topic between 1976 and 2015. In this article we discuss current knowledge on clinical features, pathogenesis, and investigative and management ...

show abstract

“…Previous studies have shown elevated IL-6 levels in the CSF of patients with ADEM which correlates with the presence of anti-MOG antibodies. [13,23,24] In MS lesions, T-cells, microglia, and activated astrocytes secrete IL-6 in the setting of augmented receptor responses [25]. This cytokine also appears to stimulate T H 17 differentiation and inhibits TGF-β Treg cell formation [25].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, there may be elevated myelin oligodendrocyte glycoprotein (MOG) antibodies, particularly in patients under 10 years of age [10,11], and higher affinity antibodies present for myelin-basic protein in children [12]. A recent study identified elevated CSF complement anaphylatoxins C5a, C4a, and C3a, and CSF IL-6 levels in children with either monophasic central demyelination or MS, higher in the former, when compared to other neurological diseases [13]. In addition, plasma MOG antibodies in monophasic disease and MS both correlated with CSF IL-6 levels.…”

Section: Introductionmentioning

confidence: 99%

Cytokine profiles in pediatric multiple sclerosis

Bhise

Balashov

Sturgill

et al. 2016

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

Background: The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood. Methods: We studied the cytokine profile in pre-treatment serum specimens of 19 pediatric MS patients, 25 adult MS patients, and 22 age-and gender-matched pediatric healthy controls. In addition to IL-2, IL-12p40, IL-12p70, IL-18, IL-23, IL-6, TNF-α, TGF-β-1, IFN-γ, IL-17A, IL-21, IL-10, IL-4, IL-5, IL-13, and GM-CSF, we measured osteopontin and soluble VCAM-I. Results: In children with MS, significantly lower levels of IL-6 were present compared to age-and gender-matched healthy control children (p < 0.05). Moreover, significantly higher levels of osteopontin (p < 0.02) and sVCAM-1 (p < 0.02) and lower levels of IL-6 (p < 0.01) were present, with trends toward lower levels of IL-12p70 (p = 0.074) and IL-17a (p = 0.05) compared to adults with MS. Conclusions: These findings indicate important differences in cytokine signatures in children with MS and suggest an unexpected possible lower inflammatory cytokine profile in children with MS.

show abstract

Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis

Cited by 41 publications

References 33 publications

Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome

Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome

Pediatric transverse myelitis

Cytokine profiles in pediatric multiple sclerosis

Contact Info

Product

Resources

About